Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...

Humira has been the world’s best selling medicine since it arrived on the market in 2002. Now, it is finally getting ...

About 58% of patients with psoriasis achieved super responder status with guselkumab, characterised by complete skin ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

After launching the skincare brand eight years ago, the founder explains how he launched the brand, why he’s stepping back, and what’s next.